

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human IL-17 RC in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) IL-17 R, rhIL-17 BR, rhIL-17 RD, or recombinant mouse IL-17 RC is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 309822
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human IL-17 RC Leu21-Ala454 Accession # NP_116121
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	K562 human chronic myelogenous leukemia cell line

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. ● 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

IL-17 receptor C (IL-17 RC; also known as IL-17 RL and IL-17 Rhom) is an 85-110 kDa member of the IL-17 receptor family. This is one of five families that currently comprise the cytokine receptor superfamily (1, 2, 3, 4, 5, 6). At this time, there are five members within the IL-17 receptor family, and these are termed IL-17 RA, B, C, D and E. Not all receptors appear to bind known members of the IL-17 cytokine family. To date, IL-17 RA is reported to bind IL-17(A), while IL-17 RB is reported to bind IL-17B and IL-17E (2, 4). Human IL-17 RC is a type I transmembrane glycoprotein that is expressed on a variety of nonhematopoietic cell types. These include endothelial cells (6, 7), chondrocytes and osteoblasts (8), breast and prostatic epithelium (6), and fibroblasts, plus renal tubular epithelium and skeletal muscle cells (8, 9). Full-length IL-17 RC is synthesized as a 791 amino acid (aa) precursor (10, 11). It contains a 20 aa signal sequence, a 518 aa extracellular domain (ECD) (aa 21-538), a 21 aa transmembrane segment, and a 232 aa cytoplasmic region. Although IL-17 RA has two fibrinogen-like regions in its ECD that contribute to its function, no such architecture has been identified in the ECD of IL-17 RC (12). Based on studies looking at exon deletions, a key ligand-binding site would appear to exist over aa 425-441 (13). The gene for human IL-17 RC contains 19 exons. It is estimated that there are over 90 alternative splice forms, with transmembrane-containing isoforms predominating (6, 14). The full-length isoform is estimated to occur approximately 10% of the time, while the three most common isoforms, as a group, occur about 50% of the time. Based on limited information, alternative splicing appears to regulate ligand specificity (13). R&D Systems IL-17 RC corresponds to IL-17 RC isoform # 3, which shows deletions of aa 36-106 and 264-278 relative to the full-length form (10). Over the ECD, IL-17 RC isoform #3 is 68% aa identical to mouse IL-17 RC ECD. IL-17 RC is the cognate receptor for IL-17F, and binds IL-17A with similar affinity (13). With IL-17 RA, it forms a definitive receptor for both IL-17A and IL-17F. The stoichiometry is unclear; it may form a heterodimer with IL-17 RA, or a heterotrimer with a preexisting IL-17 RA homodimer (4, 9, 13, 15). The heteromeric nature of the receptor may be important given that the predominant form of the IL-17 cytokine is now considered to be an IL-17A:IL-17F heterodimer (4).

References:

- Gaffen, S.L. *et al.* (2006) *Vitam. Horm.* **74**:255.
- Weaver, C.T. *et al.* (2007) *Annu. Rev. Immunol.* **25**:821.
- Moseley, T.A. *et al.* (2003) *Cytokine Growth Factor Rev.* **14**:155.
- Shen, F. and S.L. Gaffen (2008) *Cytokine* **41**:92.
- You, Z. *et al.* (2006) *Cancer Res.* **66**:175.
- You, Z. *et al.* (2007) *Neoplasia* **9**:464.
- Gerritsen, M.E. *et al.* (2003) *Br. J. Pharmacol.* **140**:595.
- Kokubu, T. *et al.* (2008) *J. Histochem. Cytochem.* **56**:89.
- Toy, D. *et al.* (2006) *J. Immunol.* **177**:36.
- GenBank Accession # Q96F46.
- Haudenschild, D. *et al.* (2002) *J. Biol. Chem.* **277**:4309.
- Kramer, J.M. *et al.* (2007) *J. Immunol.* **179**:6379.
- Kuestner, R.E. *et al.* (2007) *J. Immunol.* **179**:5462.
- Haudenschild, D.R. *et al.* (2006) *Prostate* **66**:1268.
- Kramer, J.M. *et al.* (2006) *J. Immunol.* **176**:711.

Human IL-17 RC Alexa Fluor® 647-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 309822

Catalog Number: FAB22691R
100 µg

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.